<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782080</url>
  </required_header>
  <id_info>
    <org_study_id>Stei-Sed-0106</org_study_id>
    <nct_id>NCT00782080</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of St. John´s Wort/Valerian Extract Versus Placebo in Children and Adolescents With ADHD</brief_title>
  <official_title>Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) Versus Placebo in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Huss</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Steiner Arzneimittel, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and efficacy of an herbal treatment in children and&#xD;
      adolescents with ADHD.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
        -  Randomized&#xD;
&#xD;
        -  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)&#xD;
&#xD;
        -  Placebo Control&#xD;
&#xD;
        -  Parallel Assignment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADHD is a common childhood disorder associated with attention problems and disruptive&#xD;
      behavior. Clinical evidence suggests that a herbal drug combination of St. John´s Wort&#xD;
      /Valerian extract may be effective in treating ADHD symptoms in methylphenidate and&#xD;
      atomoxetine naive patients. This study will determine the safety and efficacy of an herbal&#xD;
      treatment in children and adolescents with ADHD.&#xD;
&#xD;
      Participants will be randomly assigned to receive either an herbal product or placebo twice a&#xD;
      day for the duration of 8 weeks. Participants will come in for study visits after 2 and 8&#xD;
      weeks for the assessment of ADHD symptoms, performance and spontaneous movements. Side&#xD;
      effects will be monitored continuously and also assessed by rating scales.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD-IV rating scale</measure>
    <time_frame>Difference in total score between baseline and end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barkley´s Side Effects Rating Scale</measure>
    <time_frame>Difference between baseline and each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Sedariston</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedariston (100 mg St. John´s Wort and 50 mg Valerian extract) capsule given orally in capsules (size 1) twice daily for eight weeks in children (6-11): 1 - 0 -1 In Adolescents (12-17 years) two capsules (size 1) twice daily: 2 - 0 - 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo campsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo provided by the company given orally in capsules (size 1 )twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sedariston</intervention_name>
    <description>St. John´s Wort (100 mg) Valerian Extract (50 mg)</description>
    <arm_group_label>Sedariston</arm_group_label>
    <other_name>Sedariston Concentrate(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo campsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-IV Diagnosis of ADHD&#xD;
&#xD;
          -  Score of ADHDRS-IV-Parent Version ≥24&#xD;
&#xD;
          -  Sufficient knowledge of the German language&#xD;
&#xD;
          -  Written Informed Consent by parents and patients&#xD;
&#xD;
          -  Ability to swallow study medication&#xD;
&#xD;
          -  Sexually mature and active adolescents with highly effective methods of birth control:&#xD;
&#xD;
               -  contraception according to Pearl-Index &lt; 1&#xD;
&#xD;
               -  when use of oral contraceptives, additional methods of contraception (e.g.&#xD;
                  condoms) are necessary, i.e. double-barrier&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity against St. John´s wort or Valerian root or one of the&#xD;
             excipients&#xD;
&#xD;
          -  Known hypersensitivity of the skin when exposed to sunlight&#xD;
&#xD;
          -  All serious internal diseases, and for this reason: Current intake of the following&#xD;
             medication:&#xD;
&#xD;
               -  Ciclosporin, Tacrolimus, Indinavir and other protease inhibitors in the anti-HIV&#xD;
                  treatment&#xD;
&#xD;
               -  Irinotecan and other cytostatics&#xD;
&#xD;
               -  anticoagulants of the Cumarin-type, Digoxin, Amitriptylin, Nortriptyline&#xD;
&#xD;
               -  Midazolam, Theophylline or other medication with photosensitive effects&#xD;
&#xD;
          -  All severe psychiatric diseases except oppositional defiant disorders (according to&#xD;
             items 21-28 SNAP-IV) and conduct disorders (according to items 41-45 SNAP-IV), and for&#xD;
             this reason current intake of the following medication: antidepressants and other&#xD;
             psychotropic medication&#xD;
&#xD;
          -  Indication for hospitalization&#xD;
&#xD;
          -  Suicidality (including suicidal thoughts): Score ≥3 in item 10 of MADRS&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  IQ &lt; 70&#xD;
&#xD;
          -  Positive screening for metabolites of illegal drugs in urine&#xD;
&#xD;
          -  Previous medication with stimulants and/or atomoxetine&#xD;
&#xD;
          -  Psychotropic co-medication&#xD;
&#xD;
          -  Placement in an institution on official or judicial ruling&#xD;
&#xD;
          -  Parallel participation in another clinical trial according to German Drug Law (AMG),&#xD;
             or less than 4 weeks ago&#xD;
&#xD;
          -  Patients requiring a primary medication with methylphenidate during the study period&#xD;
             of 8 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Huss, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg University, Mainz, Dep. of Child and Adolescent Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheinhessenfachklinik</name>
      <address>
        <city>Alzey</city>
        <zip>55232</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Fachklinik für Kinder- und Jugendpsychiatrie</name>
      <address>
        <city>Bad Neuenahr</city>
        <zip>53474</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Kinder- und Jugendpsychiatrie</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité University</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Prof. Huss</investigator_full_name>
    <investigator_title>Prof. Dr. med. Dipl.-Psych. Michael Huss</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <keyword>St. John's Wort</keyword>
  <keyword>Valerian extract</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

